Renoprotective Effects of DPP-4 Inhibitors [PDF]
Antioxidants, 2021 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D).
Daiji Kawanami +4 more
doaj +7 more sources
Clinical Use of DPP-4 Inhibitors [PDF]
Frontiers in Endocrinology, 2019 DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
Baptist Gallwitz
doaj +5 more sources
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review [PDF]
MedicinaThe increasing prevalence of both type 2 diabetes mellitus and heart failure has underscored the urgent need for optimized therapeutic strategies that address the complex interplay between these conditions.
Francisco Epelde
doaj +5 more sources
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Frontiers in Molecular Biosciences, 2023 DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect. Here, the authors have presented a brief appraisal of DPP-4 inhibitors, their modes of action, and the clinical
Kunika Saini, Smriti Sharma, Yousuf Khan
doaj +3 more sources
Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data [PDF]
BMC MedicineBackground Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen +8 more
doaj +2 more sources
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis [PDF]
Journal of Diabetes Research, 2018 Objective. Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM).
Qixian Wang +8 more
doaj +2 more sources
DPP-4 Inhibition and the Path to Clinical Proof [PDF]
Frontiers in Endocrinology, 2019 In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Bo Ahrén
doaj +2 more sources
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria [PDF]
International Journal of Endocrinology, 2013 Incretin-based therapies represent one of the most promising options in type 2 diabetes treatment owing to their good effectiveness with low risk of hypoglycemia and no weight gain. Other numerous potential beneficial effects of incretin-based therapies
Martin Haluzík +2 more
doaj +2 more sources
Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention/treatment of the disruption of cardio-cerebrovascular homeostasis [PDF]
Frontiers in PharmacologyCardio-cerebrovascular diseases are increasingly prevalent worldwide, with pathological changes in the heart and brain reinforcing each other. Diabetes is a major driver of comorbidity between these two systems and contributes to poor clinical outcomes ...
Katarina Tomović Pavlović +2 more
doaj +2 more sources
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity, 2013 Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the
Gallwitz B
doaj +2 more sources